Transporter-mediated permeation of drugs across the blood-brain barrier.

Drug distribution into the brain is strictly regulated by the presence of the blood-brain barrier (BBB) that is formed by brain capillary endothelial cells. Since the endothelial cells are connected to each other by tight junctions and lack pores and/or fenestrations, compounds must cross the membranes of the cells to enter the brain from the bloodstream. Therefore, hydrophilic compounds cannot cross the barrier in the absence of specific mechanisms such as membrane transporters or endocytosis. So, for efficient supply of hydrophilic nutrients, the BBB is equipped with membrane transport systems and some of those transporter proteins have been shown to accept drug molecules and transport them into brain. In the present review, we describe mainly the transporters that are involved in drug transfer across the BBB and have been molecularly identified. The transport systems described include transporters for amino acids, monocarboxylic acids, organic cations, hexoses, nucleosides, and peptides. Most of these transporters function in the direction of influx from blood to brain; the presence of efflux transporters from brain to blood has also been demonstrated, including P-glycoprotein, MRPs, and other unknown transporters. These efflux transporters seem to be functional for detoxication and/or prevention of nonessential compounds from entering the brain. Various drugs are transported out of the brain via such efflux transporters, resulting in the decrease of CNS side effects for drugs that have pharmacological targets in peripheral tissues or in the reduction of efficacy in CNS because of the lower delivery by efflux transport. To identify the transporters functional at the BBB and to examine the possible involvement of them in drug transports by molecular and physiological approaches will provide a rational basis for controlling drug distribution to the brain.

[1]  T. Terasaki,et al.  Transport mechanism of an H1-antagonist at the blood-brain barrier: transport mechanism of mepyramine using the carotid injection technique. , 1994, Biological and Pharmaceutical Bulletin.

[2]  T. Terasaki,et al.  Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier. , 1993, The Journal of pharmacology and experimental therapeutics.

[3]  W H Oldendorf,et al.  TRANSPORT OF METABOLIC SUBSTRATES THROUGH THE BLOOD‐BRAIN BARRIER 1 , 1977, Journal of neurochemistry.

[4]  T. Nakanishi,et al.  Carrier-mediated transport of oligopeptides in the human fibrosarcoma cell line HT1080. , 1997, Cancer research.

[5]  W. Banks,et al.  Evidence that [125I]N-Tyr-delta sleep-inducing peptide crosses the blood-brain barrier by a non-competitive mechanism , 1984, Brain Research.

[6]  C. R. Crawford,et al.  Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. , 1998, Cancer research.

[7]  S. Yamada,et al.  Quantitative evaluation of brain distribution and blood-brain barrier efflux transport of probenecid in rats by microdialysis: possible involvement of the monocarboxylic acid transport system. , 1997, The Journal of pharmacology and experimental therapeutics.

[8]  Akira Tsuji,et al.  Drug delivery through the blood-brain barrier , 1996 .

[9]  F. DuBru,et al.  Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells. , 1998, Molecular pharmacology.

[10]  Y. Sugiyama,et al.  Hepatobiliary transport kinetics of HSR-903, a new quinolone antibacterial agent. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[11]  S. Yao,et al.  Transport of the antiviral nucleoside analogs 3'-azido-3'-deoxythymidine and 2',3'-dideoxycytidine by a recombinant nucleoside transporter (rCNT) expressed in Xenopus laevis oocytes. , 1996, Molecular pharmacology.

[12]  B. Zlokovic,et al.  Evidence for the Existence of a Sodium-dependent Glutathione (GSH) Transporter , 1996, The Journal of Biological Chemistry.

[13]  W. Pan,et al.  Entry of EGF into brain is rapid and saturable , 1999, Peptides.

[14]  D. Scherman,et al.  Synthesis of O-methylsulfonyl derivatives of D-glucose as potential alkylating agents for targeted drug delivery to the brain. Evaluation of their interaction with the human erythrocyte GLUT1 hexose transporter. , 1997, Carbohydrate research.

[15]  R. Rocchi,et al.  Glycodermorphins: opioid peptides with potent and prolonged analgesic activity and enhanced blood‐brain barrier penetration , 1998, British journal of pharmacology.

[16]  W. Pardridge,et al.  Blood-brain barrier transport and brain sequestration of propranolol and lidocaine. , 1984, The American journal of physiology.

[17]  J. Drewe,et al.  Transport of clonidine across cultured brain microvessel endothelial cells. , 1997, The Journal of pharmacology and experimental therapeutics.

[18]  F. Lang,et al.  Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. , 1998, Molecular pharmacology.

[19]  D. Miller,et al.  Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells. , 1998, Biochemical and biophysical research communications.

[20]  Eiji Takeda,et al.  Identification and Functional Characterization of a Na+-independent Neutral Amino Acid Transporter with Broad Substrate Selectivity* , 1999, The Journal of Biological Chemistry.

[21]  R. Bergmann,et al.  Mrp1 Multidrug Resistance‐Associated Protein and P‐Glycoprotein Expression in Rat Brain Microvessel Endothelial Cells , 1998, Journal of neurochemistry.

[22]  T. Terasaki,et al.  Sodium and Chloride Ion‐Dependent Transport of β‐Alanine Across the Blood‐Brain Barrier , 1996, Journal of neurochemistry.

[23]  W. Banks,et al.  Bidirectional saturable transport of LHRH across the blood-brain barrier. , 1991, The American journal of physiology.

[24]  W H Oldendorf,et al.  Amino acid assignment to one of three blood-brain barrier amino acid carriers. , 1976, The American journal of physiology.

[25]  T. Yamashita,et al.  Cloning and Functional Expression of a Brain Peptide/Histidine Transporter* , 1997, The Journal of Biological Chemistry.

[26]  D. Shen,et al.  Uptake of valproic acid into rat brain is mediated by a medium-chain fatty acid transporter. , 1996, The Journal of pharmacology and experimental therapeutics.

[27]  T. Tsuruo,et al.  Characterization of efflux transport of organic anions in a mouse brain capillary endothelial cell line. , 1998, The Journal of pharmacology and experimental therapeutics.

[28]  M. Segal,et al.  Identification of a saturable uptake system for deoxyribonucleosides at the blood-brain and blood-cerebrospinal fluid barriers , 1996, Brain Research.

[29]  B. Sarkadi,et al.  Transport properties of the multidrug resistance‐associated protein (MRP) in human tumour cells , 1996, FEBS letters.

[30]  Y. Sugiyama,et al.  Selective brain to blood efflux transport of para-aminohippuric acid across the blood-brain barrier: in vivo evidence by use of the brain efflux index method. , 1997, The Journal of pharmacology and experimental therapeutics.

[31]  H. Davson,et al.  Kinetics of arginine-vasopressin uptake at the blood-brain barrier. , 1990, Biochimica et biophysica acta.

[32]  T. Terasaki,et al.  In vivo and in vitro evidence for a common carrier mediated transport of choline and basic drugs through the blood-brain barrier. , 1990, Journal of pharmacobio-dynamics.

[33]  R. Egleton,et al.  Transport of opioid peptides into the central nervous system. , 1998, Journal of pharmaceutical sciences.

[34]  W. Pardridge,et al.  Transport of histone through the blood-brain barrier. , 1989, The Journal of pharmacology and experimental therapeutics.

[35]  S. Futaki,et al.  Adamantane as a brain-directed drug carrier for poorly absorbed drug. 2. AZT derivatives conjugated with the 1-adamantane moiety. , 1994, Journal of pharmaceutical sciences.

[36]  K. Pettigrew,et al.  Entry of opioid peptides into the central nervous system. , 1980, Science.

[37]  T. Terasaki,et al.  In‐vitro Evidence for Carrier‐mediated Uptake of Acidic Drugs by Isolated Bovine Brain Capillaries , 1991, The Journal of pharmacy and pharmacology.

[38]  T. Kodaki,et al.  Cloning, Expression, and Characterization of a Novel Phospholipase D Complementary DNA from Rat Brain* , 1997, The Journal of Biological Chemistry.

[39]  W. Oldendorf,et al.  Independent blood-brain barrier transport systems for nucleic acid precursors. , 1975, Biochimica et biophysica acta.

[40]  D. Griffith,et al.  Nucleoside and nucleobase transport systems of mammalian cells. , 1996, Biochimica et biophysica acta.

[41]  N. Kaplowitz,et al.  Evidence for carrier-mediated transport of glutathione across the blood-brain barrier in the rat. , 1990, The Journal of clinical investigation.

[42]  T. Terasaki,et al.  Na(+)- and Cl(-)-dependent transport of taurine at the blood-brain barrier. , 1995, Biochemical pharmacology.

[43]  J. Drewe,et al.  Transport of the β-Lactam Antibiotic Benzylpenicillin and the Dipeptide Glycylsarcosine by Brain Capillary Endothelial Cells In Vitro , 1998 .

[44]  W. Banks,et al.  Bidirectional transport of interleukin-1 alpha across the blood-brain barrier , 1989, Brain Research Bulletin.

[45]  V. Erspamer,et al.  Deltorphin transport across the blood-brain barrier. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J. Nezu,et al.  Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. , 1999, The Journal of pharmacology and experimental therapeutics.

[47]  Bradley E. Enerson,et al.  Expression of monocarboxylate transporter MCT1 by brain endothelium and glia in adult and suckling rats. , 1997, The American journal of physiology.

[48]  C. R. Crawford,et al.  Nucleoside transport in normal and neoplastic cells. , 1993, Advances in enzyme regulation.

[49]  I. Tamai,et al.  Carrier-mediated or specialized transport of drugs across the blood-brain barrier. , 1999, Advanced drug delivery reviews.

[50]  Y. Sugiyama,et al.  In vivo evidence for carrier-mediated efflux transport of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine across the blood-brain barrier via a probenecid-sensitive transport system. , 1997, The Journal of pharmacology and experimental therapeutics.

[51]  H. Takanaga,et al.  Immunohistochemical and Functional Characterization of pH‐dependent Intestinal Absorption of Weak Organic Acids by the Monocarboxylic Acid Transporter MCT1 , 1999, The Journal of pharmacy and pharmacology.

[52]  T. Tsuruo,et al.  Efflux Transport of Tolbutamide Across the Blood‐brain Barrier , 1998, The Journal of pharmacy and pharmacology.

[53]  D. Sitar,et al.  Ability of nitrobenzylthioinosine to cross the blood-brain barrier in rats , 1996, Neuroscience Letters.

[54]  Q. Smith,et al.  Identification of the Cationic Amino Acid Transporter (System y+) of the Rat Blood‐Brain Barrier , 1993, Journal of neurochemistry.

[55]  Y. Kanai,et al.  Cloning and Characterization of a Novel Multispecific Organic Anion Transporter * , 1997 .

[56]  W. Pardridge,et al.  Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport. , 1987, The Journal of biological chemistry.

[57]  T. Terasaki,et al.  Acidic drug transport in vivo through the blood-brain barrier. A role of the transport carrier for monocarboxylic acids. , 1990, Journal of pharmacobio-dynamics.

[58]  W. Banks,et al.  D-[Ala1]-peptide T-Amide is transported from blood to brain by a saturable system , 1987, Brain Research Bulletin.

[59]  J. H. Beijnen,et al.  Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs , 1994, Cell.

[60]  C. Cass,et al.  Demonstration of the existence of mRNAs encoding N1/cif and N2/cit sodium/nucleoside cotransporters in rat brain. , 1996, Brain research. Molecular brain research.

[61]  C. Cass,et al.  Distribution of Equilibrative, Nitrobenzylthioinosine‐Sensitive Nucleoside Transporters (ENT1) in Brain , 1999, Journal of neurochemistry.

[62]  W R Woodward,et al.  The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. , 1984, The New England journal of medicine.

[63]  Q. Smith,et al.  Introduction to the Blood–Brain Barrier: Blood–brain barrier amino acid transport , 1998 .

[64]  D. Roden,et al.  The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. , 1998, The Journal of clinical investigation.

[65]  T. Terasaki,et al.  Absorptive-mediated endocytosis of a dynorphin-like analgesic peptide, E-2078 into the blood-brain barrier. , 1989, The Journal of pharmacology and experimental therapeutics.

[66]  W H Oldendorf,et al.  Carrier-mediated blood-brain barrier transport of short-chain monocarboxylic organic acids. , 1973, The American journal of physiology.

[67]  I. Tamai,et al.  Efflux transport of a new quinolone antibacterial agent, HSR-903, across the blood-brain barrier. , 1999, The Journal of pharmacology and experimental therapeutics.

[68]  Y. Sugiyama,et al.  Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR. , 1997, The American journal of physiology.

[69]  H. Kusuhara,et al.  P-Glycoprotein mediates the efflux of quinidine across the blood-brain barrier. , 1997, The Journal of pharmacology and experimental therapeutics.

[70]  L. Rakić,et al.  Slow Penetration of Thyrotropin‐Releasing Hormone Across the Blood‐Brain Barrier of an In Situ Perfused Guinea Pig Brain , 1988, Journal of neurochemistry.

[71]  M. Segal,et al.  Saturation kinetics, specificity and NBMPR sensitivity of thymidine entry into the central nervous system , 1997, Brain Research.

[72]  W. Pardridge,et al.  Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. , 1991, The Journal of pharmacology and experimental therapeutics.

[73]  R. Kalaria,et al.  Nucleoside Transporter of Cerebral Micro vessels and Choroid Plexus , 1986, Journal of neurochemistry.

[74]  T. Terasaki,et al.  Transport of monocarboxylic acids at the blood-brain barrier: studies with monolayers of primary cultured bovine brain capillary endothelial cells. , 1991, The Journal of pharmacology and experimental therapeutics.

[75]  H. Sasabe,et al.  Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats. , 1998, The Journal of pharmacology and experimental therapeutics.

[76]  Richard G. W. Anderson,et al.  Molecular characterization of a membrane transporter for lactate, pyruvate, and other monocarboxylates: Implications for the Cori cycle , 1994, Cell.

[77]  J. Nezu,et al.  Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. , 1999, The Journal of pharmacology and experimental therapeutics.

[78]  N. Kaplowitz,et al.  Transport of glutathione at blood-brain barrier of the rat: inhibition by glutathione analogs and age-dependence. , 1992, The Journal of pharmacology and experimental therapeutics.

[79]  T. Yamashima,et al.  In vivo and in vitro evidence for ATP-dependency of P-glycoprotein-mediated efflux of doxorubicin at the blood-brain barrier. , 1995, Biochemical pharmacology.

[80]  S. Yao,et al.  Cloning and functional expression of a complementary DNA encoding a mammalian nucleoside transport protein. , 1994, The Journal of biological chemistry.

[81]  C. Shoemaker,et al.  Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family , 1998, Nature.

[82]  A. Schinkel,et al.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. , 1996, The Journal of clinical investigation.

[83]  B. Zlokovic,et al.  Evidence for transcapillary transport of reduced glutathione in vascular perfused guinea-pig brain. , 1994, Biochemical and Biophysical Research Communications - BBRC.

[84]  A. Artru,et al.  Contribution of probenecid-sensitive anion transport processes at the brain capillary endothelium and choroid plexus to the efficient efflux of valproic acid from the central nervous system. , 1994, The Journal of pharmacology and experimental therapeutics.

[85]  W. Pardridge,et al.  Low blood–brain barrier permeability to azidothymidine (AZT), 3TC™, and thymidine in the rat , 1998, Brain Research.

[86]  H. Christensen,et al.  Role of amino acid transport and countertransport in nutrition and metabolism. , 1990, Physiological reviews.

[87]  J. Schuetz,et al.  MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs , 1999, Nature Medicine.

[88]  Y. Sugiyama,et al.  Efflux of taurocholic acid across the blood-brain barrier: interaction with cyclic peptides. , 1998, The Journal of pharmacology and experimental therapeutics.

[89]  E. Cornford The blood-brain barrier, a dynamic regulatory interface , 1985 .

[90]  M C Willingham,et al.  Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. , 1989, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[91]  K. Giacomini,et al.  Role of organic cation transporters in drug absorption and elimination. , 1998, Annual review of pharmacology and toxicology.

[92]  S. Yao,et al.  Molecular cloning and characterization of a nitrobenzylthioinosine-insensitive (ei) equilibrative nucleoside transporter from human placenta. , 1997, The Biochemical journal.

[93]  H. Davson,et al.  Kinetic Analysis of Leucine‐Enkephalin Cellular Uptake at the Luminal Side of the Blood‐Brain Barrier of an In Situ Perfused Guinea‐Pig Brain , 1989, Journal of neurochemistry.

[94]  G. Tsujimoto,et al.  Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter , 1999, Nature Genetics.

[95]  T. Tsuruo,et al.  GSH Transport in Immortalized Mouse Brain Endothelial Cells , 1999, Journal of neurochemistry.

[96]  R. Spector,et al.  Localization and Mechanism of Thymidine Transport in the Central Nervous System , 1982, Journal of neurochemistry.

[97]  S. Yao,et al.  Cloning of a human nucleoside transporter implicated in the Cellular uptake of adenosine and chemotherapeutic drugs , 1997, Nature Medicine.

[98]  Y. Sai,et al.  Design and Synthesis of Peptides Passing through the Blood-Brain Barrier , 1998 .

[99]  W. Pardridge,et al.  Differential glycosylation of the GLUT1 glucose transporter in brain capillaries and choroid plexus. , 1994, Biochimica et biophysica acta.

[100]  I. Tamai,et al.  Blood-brain barrier function of P-glycoprotein , 1997 .

[101]  Y. Sai,et al.  Structure-internalization relationship for adsorptive-mediated endocytosis of basic peptides at the blood-brain barrier. , 1997, The Journal of pharmacology and experimental therapeutics.

[102]  Eiji Takeda,et al.  Expression Cloning and Characterization of a Transporter for Large Neutral Amino Acids Activated by the Heavy Chain of 4F2 Antigen (CD98)* , 1998, The Journal of Biological Chemistry.

[103]  F. Roux,et al.  Evidence for an Alanine, Serine, and Cysteine System of Transport in Isolated Brain Capillaries , 1987, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[104]  W. Pardridge,et al.  P-glycoprotein on astrocyte foot processes of unfixed isolated human brain capillaries , 1999, Brain Research.

[105]  W. Pardridge,et al.  Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[106]  V. Ganapathy,et al.  Identity of the Organic Cation Transporter OCT3 as the Extraneuronal Monoamine Transporter (uptake2) and Evidence for the Expression of the Transporter in the Brain* , 1998, The Journal of Biological Chemistry.

[107]  D. W. Beck,et al.  Uptake of adenosine into cultured cerebral endothelium , 1983, Brain Research.

[108]  Y. Sawada,et al.  Uptake of propranolol by microvessels isolated from bovine brain. , 1987, Journal of pharmaceutical sciences.

[109]  Y. Okada,et al.  A sodium- and energy-dependent glucose transporter with similarities to SGLT1–2 is expressed in bovine cortical vessels , 1995, Neuroscience Research.

[110]  A. Schinkel,et al.  P-Glycoprotein, a gatekeeper in the blood-brain barrier. , 1999, Advanced drug delivery reviews.

[111]  M. Reiss,et al.  Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells. , 1993, Biochemical pharmacology.

[112]  J. Nezu,et al.  Molecular and Functional Identification of Sodium Ion-dependent, High Affinity Human Carnitine Transporter OCTN2* , 1998, The Journal of Biological Chemistry.

[113]  W. Pardridge,et al.  Blood–Brain Barrier Transport of Valproic Acid , 1985, Journal of neurochemistry.

[114]  V. Hruby,et al.  The entry of [D-penicillamine2,5]enkephalin into the central nervous system: saturation kinetics and specificity. , 1997, The Journal of pharmacology and experimental therapeutics.

[115]  R. Spector,et al.  Deoxycytidine Transport and Metabolism in the Central Nervous System , 1983, Journal of neurochemistry.

[116]  V A Levin,et al.  Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. , 1980, Journal of medicinal chemistry.

[117]  T. Tsuruo,et al.  In vivo and in vitro evidence of blood-brain barrier transport of a novel cationic arginine-vasopressin fragment 4-9 analog. , 1999, The Journal of pharmacology and experimental therapeutics.

[118]  W. Pardridge Brain metabolism: a perspective from the blood-brain barrier. , 1983, Physiological reviews.

[119]  H. Galla,et al.  Evidence for an asymmetrical uptake of L-carnitine in the blood-brain barrier in vitro. , 1997, Biochemical and biophysical research communications.

[120]  T. Henthorn,et al.  Active transport of fentanyl by the blood-brain barrier. , 1999, The Journal of pharmacology and experimental therapeutics.

[121]  T. Tsuruo,et al.  [Functional involvement of P-glycoprotein in blood-brain barrier]. , 1992, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[122]  H. Yamamoto,et al.  cDNA cloning and functional characterization of rat intestinal monocarboxylate transporter. , 1995, Biochemical and biophysical research communications.

[123]  D. Torrents,et al.  Identification of a Membrane Protein, LAT-2, That Co-expresses with 4F2 Heavy Chain, an L-type Amino Acid Transport Activity with Broad Specificity for Small and Large Zwitterionic Amino Acids* , 1999, The Journal of Biological Chemistry.

[124]  J. Nezu,et al.  Cloning and characterization of a novel human pH‐dependent organic cation transporter, OCTN1 , 1997, FEBS letters.

[125]  M. S. D. Pino,et al.  Neutral amino acid transport by the blood-brain barrier. Membrane vesicle studies. , 1992, The Journal of biological chemistry.

[126]  R. Starzyk,et al.  Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[127]  W. Pardridge Peptide drug delivery to the brain , 1991 .

[128]  P. Borst,et al.  Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. , 1995, The Journal of clinical investigation.

[129]  W. Pardridge,et al.  Blood-brain barrier transport and brain metabolism of adenosine and adenosine analogs. , 1994, The Journal of pharmacology and experimental therapeutics.

[130]  V. Hruby,et al.  Glycopeptide enkephalin analogues produce analgesia in mice: evidence for penetration of the blood-brain barrier. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[131]  J. Phillis,et al.  Uptake of Adenosine by Isolated Rat Brain Capillaries , 1982, Journal of neurochemistry.

[132]  T. Tsuruo,et al.  P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. , 1992, Life sciences.

[133]  T. Terasaki,et al.  Transport mechanism of a new behaviorally highly potent adrenocorticotropic hormone (ACTH) analog, ebiratide, through the blood-brain barrier. , 1991, The Journal of pharmacology and experimental therapeutics.

[134]  T. Tsuruo,et al.  High-affinity efflux transport system for glutathione conjugates on the luminal membrane of a mouse brain capillary endothelial cell line (MBEC4). , 1999, The Journal of pharmacology and experimental therapeutics.

[135]  R. Egleton,et al.  Transport of the delta-opioid receptor agonist [D-penicillamine2,5] enkephalin across the blood-brain barrier involves transcytosis1. , 1999, Journal of pharmaceutical sciences.

[136]  C. Chen,et al.  Blood-brain disposition and antinociceptive effects of -D-penicillamine2,5-enkephalin in the mouse. , 1997, The Journal of pharmacology and experimental therapeutics.

[137]  A. Terry,et al.  Inhibition of brain choline uptake by isoarecolone and lobeline derivatives: implications for potential vector-mediated brain drug delivery , 1998, Neuroscience Letters.